Study: Hypertension drug may slow progression of eye disease in Type 1 diabetes patients
MINNEAPOLIS Drugs used to treat hypertension might slow the progression of eye disease in patients with Type 1 diabetes, according to a new study.
Michael Mauer, a researcher at the University of Minnesota, split a group of patients into two groups, giving Merck’s Cozaar (losartan) to one group, enalapril to another and a placebo to the third. Mauer and his colleagues found that after five years, 65% to 70% patients who received Cozaar and enalapril experienced a slowing of the progression of diabetic eye injury. Enalapril is the chemical name of Biovail Labs’ Vasotec, which is available as a generic.
Diabetes is the biggest cause of acquired blindness in adults and causes nearly half of all new cases of chronic kidney failure in the United States each year, though the study did not find the antihypertensive drugs delayed early kidney tissue injury.
“The secondary results of this study showed that people taking these antihypertensive medications experienced a substantially positive effect in slowing diabetic eye injury,” Mauer stated.
Mylan gets FDA approval for AstraZeneca drug generic
PITTSBURGH The Food and Drug Administration has approved Mylan’s generic version of a drug for treating prostate cancer.
Mylan announced Tuesday the approval of bicalutamide tablets in the 50-mg strength. The tablets are a generic version of AstraZeneca’s Casodex, which had U.S. sales of $322 million for the 12 months ended March 31 in the same strength, according to IMS Health data, and global sales of $1.26 billion, according to AstraZeneca financial data.
Teva announced Monday the launch of its own version of the drug.
Merck shareholders approve merger with Schering-Plough
WHITEHOUSE STATION, N.J. It’s official: Merck & Co.’s shareholders have approved its merger with Schering-Plough.
Merck announced Friday that its shareholders voted overwhelmingly to approve the proposed merger. The preliminary tabulation indicates that more than 99% of the company’s outstanding shares voted in favor of the transaction. Merck held its special shareholder meeting in Bridgewater, N.J. on Friday to vote on the proposed merger.
“We are gratified by the shareholder confidence demonstrated through the outcome of today’s vote,” said Richard T. Clark, Merck’s chairman, president and CEO. “On behalf of Merck’s Board and management team, I want to thank our shareholders, customers and dedicated employees for their support throughout this process. We look forward to completing the merger with Schering-Plough and to creating a strong, global leader that can make a substantial difference to patients and global health care.”
As previously announced on March 9, under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 of a share of new Merck common stock and $10.50 in cash for each share of Schering-Plough. For Merck shareholders, existing Merck share certificates will automatically represent an equal number of shares in the new Merck after completion of the merger.
The company expects the transaction to close in the fourth quarter of 2009, as originally planned. The transaction remains subject to the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the SEC Merger Regulation and certain other foreign jurisdictions.
All proxy cards and ballots submitted at the special meeting were processed by IVS Associates Inc. for final tabulation and certification. Final voting results will be publicly announced promptly after they have been tabulated and certified.